USSTOCK.TODAY
Weekend. Closed
Log in Sign up

Novo shares plunge over 60% amid clinical failure and intensifying competition

The Motley Fool +1 ·

  1. 1Novo's stock price has fallen by more than 60% over the past two years.
  2. 2Novo recorded a 2% increase in net sales compared to the same period last year.
  3. 3Novo's current forward price-to-earnings ratio stands at 11.8x.

So what's the key point?

Novo's stock price has dropped by more than 60% over a two-year period. As the rate of sales growth has slowed, the figure showing the stock price level relative to earnings has also been revealed.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

CoreWeave CEO Sells Approximately $1 Billion in Shares Following IPO TIKR · 1h agoSpaceX accelerates telecom competition with $8 billion spectrum acquisition The Motley Fool +1 · 1h agoiShares Core Dividend (DIVB) ETF Outperforms S&P 500 Kiplinger · 1h ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news